Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Shuttle Pharmaceuticals Holdings Inc

SHPH ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$4.07

▼ -11.14%

Market Cap $4.18M · Vol 7.31K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.18M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

62.69

Momentum

Beta

1.30

vs Market

52W High

$55.90

92.72% below

52W Low

$2.62

55.34% above

Volume

7.31K

Avg 260.91K

P/B

1.62

Price-to-book

ROE

N/A

Return on equity

Free Float

96.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Shuttle Pharmaceuticals Holdings Inc (SHPH) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SHPH pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.65%

-2.16%

-36.41%

-63.33%

YTD

-77.39%

-88.37%

-99.76%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,721,670.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-180.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.62
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.03M

Technical Indicators

50-Day SMA	$3.72
200-Day SMA	$11.27
RSI (14)	62.69
Beta	1.30
52-Week High	$55.90
52-Week Low	$2.62

Volume Today	7.31K
Avg Daily Volume (30D)	260.91K
Relative Volume	0.03x
Volatility (10D)	161.93
Volatility (30D)	174.31
Free Float	96.10%

Analyst Consensus

N/A

Current Price $4.07

Mean Target N/A

52W Low$2.62 52W High$55.90

Current

Target

$2.62 $55.90

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG017Z2NGC6

ISINUS8256935003

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.